# Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients

> **NCT04393311** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Stanford University**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ulinastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04393311
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-02
- **Primary completion:** 2022-08
- **Final completion:** 2022-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Discontinuation of drug candidates
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04393311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04393311, "Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04393311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*